CancerFax

11/02/2026

🚀 Exciting News—CancerFax Featured in USA News!

We're proud to share that CancerFax has been featured in USA News in a powerful story titled "From Personal Loss to Global Impact: CancerFax Revolutionizes Access to Advanced Cancer Treatment."

The piece highlights how CancerFax was born out of a deeply personal experience with cancer and how that journey fueled a mission to transform the way patients around the world access cutting-edge cancer treatments, including CAR-T cell therapy and other advanced immunotherapies.

Here's what the article covers:

Our Origin Story: How personal loss became the catalyst for building a platform dedicated to bridging the gap between cancer patients and life-saving treatments.

Breaking Barriers: CancerFax is making advanced cancer therapies once limited to a few countries and institutions accessible to patients globally, helping them navigate treatment options, clinical trials, and top oncology centers worldwide.

A Global Mission: Our commitment to ensuring that geography and financial constraints don't stand between a patient and the best possible care.

This recognition reaffirms our dedication to every patient and family navigating a cancer diagnosis. We're just getting started.

🔗 Read the full article here: https://bit.ly/4qvmZCe

CancerFax delivers advanced cancer care with global connections and therapies, offering hope and healing in tough times.

05/02/2026

🧬 Breakthrough: 100% Response Rate in Advanced Cervical Cancer Study!

Are you or a loved one seeking the latest advancements in treatment? A landmark Phase II study has revealed a major breakthrough for patients with stage IIB-IVA locally advanced cervical carcinoma.

The Key Finding:
When standard radiotherapy was combined with weekly intratumoral injections of rAd-p53 gene therapy (Gendicine), the overall response rate reached a staggering 100%, compared to just 72.2% with radiation alone.

Why This Matters:

Superior Efficacy: Over 52% of patients in the gene therapy group achieved a Complete Response (CR).

Enhanced Safety: The therapy was well-tolerated, with the most common side effect being a manageable, self-limited fever.

Zero Progression: No patients in the combination group saw their disease progress during the study period.

At CancerFax, we are dedicated to connecting patients worldwide with cutting-edge therapies like gene therapy, CAR T-cell therapy, and global clinical trials. Our end-to-end concierge service ensures you have access to the most advanced oncology centers in the USA, China, and beyond.

Don't settle for standard care when innovation is available.

🔗 Learn more about advanced treatment options at: https://cancerfax.com

Call/WhatsApp for a Free Consultation: (213) 789-5655

04/02/2026

Today, on World Cancer Day, we stand united in the fight against cancer. 💙

At CancerFax, we're committed to connecting patients with cutting-edge immunotherapy and cellular therapy treatments that offer new hope and possibilities. Every day, we work to bridge the gap between innovative cancer care and those who need it most.

This World Cancer Day, let's remember: early detection saves lives, research brings hope, and together, we are stronger than cancer.
To everyone affected by cancer—patients, survivors, caregivers, and medical professionals—we see you, we support you, and we're here for you.

Let's continue to push boundaries, share knowledge, and fight for a world where cancer is no longer a life sentence.

Together, we can close the care gap. 🌍

07/01/2026

Clinical Trials Alert | Chinese Academy of Medical Sciences, National Cancer Center

A new recruitment call is now open for a promising lung cancer clinical trial in China. Researchers at the National Cancer Center are evaluating a combination of inhaled mRNA vaccine with bevacizumab (VEGF/PD-1 bispecific antibody).

This study is enrolling patients with:
• Chemotherapy-resistant lung cancer
• Adenocarcinoma or squamous cell carcinoma
• Cases with or without genetic mutations

The trial aims to investigate whether this dual-immunotherapy approach can enhance anti-tumor activity and open new options for patients who have limited treatment choices left.

If you or someone you know is seeking advanced treatment pathways, this may be worth considering.

📩 For eligibility checks and enrollment support:

WeChat / WhatsApp: +86 182 1759 2149

CancerFax | Advanced Cancer Treatment Management

13/12/2025

Did you know China alone has over 18,000 active clinical trials focused on cancer treatment right now?

Clinical trials are not blind experiments. They are carefully designed pathways that bring tomorrow’s treatments to patients today. From targeted therapies and immunotherapy to advanced cell and gene treatments, this is where real progress happens.

Are you curious about the workings of clinical trials? We are taking you behind the scenes with insights from researchers, doctors, and real patient experiences that show what participation truly looks like.

If you or a loved one is exploring advanced treatment options, this section is worth a closer look.

👉 Explore ongoing cancer clinical trials here:

https://cancerfax.com/clinical-trials/

Uncover the power of cancer clinical Trials in China! Discover how they shape treatment strategies. Learn about effectiveness & side Effects of our clinical trials.

12/12/2025

GD2 CAR-T Cell Therapy: A New Hope for Neuroblastoma

Neuroblastoma remains one of the most challenging childhood cancers, especially in relapsed or high-risk cases. GD2 CAR-T cell therapy is emerging as a powerful option by engineering a patient’s own T cells to specifically target GD2, a marker highly expressed on neuroblastoma cells.

Early clinical studies have shown encouraging response rates, improved disease control, and the potential for durable remission in children who have exhausted standard treatments. With advances in CAR design and safety management, GD2 CAR-T therapy is opening a new chapter in pediatric oncology and offering renewed

09/12/2025

3 Signs to Look for During a Breast Cancer Self-Check

This video includes:
1) Breast self exam
2) Breast self examination
3) How to do a breast self-exam
4) Breast cancer self check
5) Breast cancer self exam

Breast self-exams aren’t a diagnosis, but they help you stay aware of changes in your body. Here are three key signs that deserve attention:

1. A new lump or thickened area

If you notice a lump that feels different from the rest of the breast tissue or from the other breast, don’t ignore it. Most lumps are non-cancerous, but any new or persistent lump should be checked by a doctor.

2. Visible changes in breast shape or skin

Look for dimpling, puckering, swelling, or skin that resembles an orange peel. Also observe any sudden change in size or shape. These are subtle clues that something may be going on beneath the surface.

3. Ni**le changes or unusual discharge

If the ni**le turns inward, changes position, becomes scaly, or starts releasing discharge (especially if it’s bloody or occurs without squeezing), it’s worth getting evaluated.

BreastHealth KnowTheSigns CancerPrevention WomenHealthCare BeBreastAware CheckYourBreasts

09/12/2025

CAR-T Cell Therapy Targeting NKG2DL-Positive Solid Tumors

Researchers at the Chinese Academy of Medical Sciences and the National Cancer Center are developing a new type of CAR-T cell therapy that specifically targets solid tumors with NKG2DL, which are often found in aggressive cancers. This approach targets stress-induced ligands, which are commonly expressed on many aggressive cancers, thereby enabling a broader and more precise anti-tumor response.

These ongoing clinical trials aim to overcome long-standing barriers in solid tumor treatment, including resistance, immune evasion, and limited therapeutic options. If successful, NKG2DL-CAR-T could offer a promising path for patients who have exhausted conventional therapies.

If you or your loved one is exploring advanced treatment options, we can help with eligibility checks and enrollment guidance.

📩 WeChat / WhatsApp: +86 182 1759 2149

CancerFax | Advanced Cancer Treatment Management

07/12/2025

Personalized, AI-Driven TCRT-T Cell Therapy: Now in Clinical Trials at CAMS, National Cancer Center, Beijing

A new generation of cancer treatment is taking shape in China. Researchers at CAMS, National Cancer Center, are running clinical trials on personalized, AI-driven, multi-targeted TCRT-T cell therapy.

This approach combines deep-learning prediction models with advanced T-cell engineering to identify the most effective TCR targets for each patient. Instead of relying on a single marker, the therapy can address multiple tumor antigens at once, improving the chances of a durable response and reducing relapse.

These trials may offer new hope for patients who have exhausted conventional options, especially in solid tumors where CAR-T has had limitations.

If you want to check eligibility, understand costs, or explore travel and treatment support in China, we’re here to guide you every step of the way.

📩 WeChat / WhatsApp: +86 182 1759 2149

CancerFax | Advanced Cancer Treatment Support Worldwide

05/12/2025

✨ Hope on the horizon for liver cancer patients: GPC3 CAR-T therapy ✨

Liver cancer (especially advanced Hepatocellular carcinoma, HCC) is hard to treat but recent advances in immunotherapy are offering real reason for optimism. One of the most promising strategies: CAR-T cells engineered to target Glypican‑3 (GPC3), a protein often found on HCC cells but rarely on healthy cells.

What makes GPC3 CAR-T therapy special?

GPC3 is overexpressed in many HCC tumors, making it a useful “flag” for the immune system to recognize cancer cells while sparing healthy tissue. PMC

Preclinical and early clinical studies have shown that CAR-T cells targeting GPC3 can kill liver cancer cells effectively. Early lab trials showed strong anti-tumor activity.

What does the data say so far?

A newer “armored” version, C-CAR031 a next-generation GPC3 CAR-T showed strong results in early trials: in a 2024 report, among evaluable patients (with advanced HCC), ~90.9% showed tumor reduction; disease control rate was 90.9%, and objective response rate was 50.0% (rising to 57.1% at the highest dose level).

If you or someone you know wants to learn more about ongoing trials or GPC3-CAR-T therapy, feel free to reach out.

📞 Contact: CancerFax
WeChat / WhatsApp: +86 182 1759 2149

03/12/2025

CAR T-Cell Therapy: Changing the Way We Fight Cancer

Most cancer treatments try to attack the tumor from the outside. CAR T-cell therapy takes a very different path. It turns a patient’s own immune cells into trained fighters that can recognize and destroy cancer with remarkable precision.

By modifying T-cells in a lab and re-infusing them back into the body, doctors are seeing results that were once impossible in conditions like lymphoma, leukemia, and multiple myeloma. Many patients who had exhausted all standard options are now achieving strong, lasting responses.

The best part? This field keeps moving forward. New targets like CD7, CD22, BCMA, Claudin 18.2, and GPC3 are opening doors for more patients every year.

If you or someone you know is exploring advanced cancer treatments, CAR T-cell therapy is one option worth understanding deeply. At CancerFax, we help patients access cutting-edge cellular therapies at leading hospitals in China and India.

Hope, science, and real outcomes are coming together like never before.